Andrew D. Schiermeier

2019

In 2019, Andrew D. Schiermeier earned a total compensation of $1.2M as Executive Vice President, Chief Operating Officer at Intellia Therapeutics, a 58% decrease compared to previous year.

Compensation breakdown

Bonus$167,200
Option Awards$611,897
Salary$440,000
Other$8,778
Total$1,227,875

Schiermeier received $611.9K in option awards, accounting for 50% of the total pay in 2019.

Schiermeier also received $167.2K in bonus, $440K in salary and $8.8K in other compensation.

Rankings

In 2019, Andrew D. Schiermeier's compensation ranked 8,316th out of 13,971 executives tracked by ExecPay. In other words, Schiermeier earned more than 40.5% of executives.

ClassificationRankingPercentile
All
8,316
out of 13,971
41st
Division
Manufacturing
3,288
out of 5,701
42nd
Major group
Chemicals And Allied Products
1,247
out of 2,200
43rd
Industry group
Drugs
1,060
out of 1,886
44th
Industry
In Vitro and In Vivo Diagnostic Substances
30
out of 77
61st
Source: SEC filing on April 24, 2020.

Schiermeier's colleagues

We found four more compensation records of executives who worked with Andrew D. Schiermeier at Intellia Therapeutics in 2019.

2019

Laura Sepp-Lorenzino

Intellia Therapeutics

Chief Scientific Officer

2019

John Leonard

Intellia Therapeutics

Chief Executive Officer

2019

José Rivera

Intellia Therapeutics

General Counsel

2019

Glenn Goddard

Intellia Therapeutics

Chief Financial Officer

News

You may also like